Methylglyoxal as a Convergent Mediator of Diabetic Complications: Generation, Protein Targets, Tissue Distribution, and Therapeutic Reduction—A Clinically Oriented Mechanistic Synthesis

Abstract

Methylglyoxal (MGO), a highly reactive 1,2-dicarbonyl, is generated by all three principal pathways of advanced glycation end product (AGE) synthesis in type 2 diabetes mellitus (T2DM)—the Hodge, Namiki, and Wolff pathways—and by the non-enzymatic degradation of glycolytic triose phosphates. It is the principal substrate of the glutathione-dependent GLO1/GLO2 glyoxalase system and the main source of the hydroimidazolone-1 (MG-H1) adduct, and it directly modifies intracellular proteins across multiple tissues. This clinically oriented narrative review synthesizes dicarbonyl chemistry, glyoxalase, and AGE adduct research to propose—as a hypothesis-generating schema rather than established biology—that MGO functions as a convergent biochemical node in diabetic complications. We examine MGO generation across the four input routes, its preferential modification of arginine and lysine residues, the correspondence between tissue MGO accumulation and complication distribution, glyoxalase-mediated clearance, and therapeutic strategies. We further propose that routine parameters such as gamma-glutamyl transferase and red cell distribution width may serve as accessible proxies for MGO burden, with the explicit caveat that these mappings require prospective validation and do not constitute a validated clinical instrument.